This is a non-core endpoint: only basic statistics are computed.
See its core counterpart C3_LEIOMYOSARCOMA_EXALLC for full statistics.
Leiomyosarcoma
C3_LEIOMYOSARCOMA
No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
237 |
4. Check minimum number of eventsNone |
237 |
5. Include endpointsNone |
237 |
6. Filter based on genotype QC (FinnGen only) |
237 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- First used in FinnGen datafreeze
- DF8
Similar endpoints
↥List of similar endpoints to
Leiomyosarcoma
based on the number of shared cases.
Similar with more cases:
- Leiomyosarcoma, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm
- Any event in cancer register
- Malignant neoplasm, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm, wide definition for exclusion
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 237 | 160 | 77 |
| Unadjusted period prevalence (%) | 0.05 | 0.05 | 0.03 |
| Median age at first event (years) | 59.86 | 57.17 | 65.45 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 218
- Matched controls
- 2177
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
C54.21
ICD-10 Finland
Leiomyosarcoma and myometrium
+∞
74.3
67
*
8890/3-C54.9
ICD-O-3
Leiomyosarcoma, NOS, of corpus uteri
+∞
40.9
38
*
128
Kela drug reimbursment
Cancers of female genital organs
36.3
34.6
44
15
8890/3-C49.2
ICD-O-3
Leiomyosarcoma, NOS, of connective, Subcutaneous and other soft tissues of lower limb and hip
+∞
34.3
32
*
H02AB02
ATC
dexamethasone; systemic
8.8
33.7
81
137
8890/3-C54.2
ICD-O-3
Leiomyosarcoma, NOS, of myometrium
+∞
31.0
29
*
C49.23
ICD-10 Finland
Malignant tumor of connective tissue and soft tissue of lower extremity including hip leiomyosarcoma
348.0
30.6
30
*
130
Kela drug reimbursment
Malignant tumour
9.2
30.0
68
102
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
14.7
28.5
49
42
159
Kela drug reimbursment
Pazopanib
293.6
26.3
26
*
C54.2
ICD-10 Finland
Malignant neoplasm: Myometrium
+∞
25.5
24
*
JN4BD
NOMESCO Finland
Extensive body CT
6.7
24.8
71
147
L03AA13
ATC
pegfilgrastim; parenteral
13.2
24.5
44
41
C48.03
ICD-10 Finland
Malignant tumor of the retroperitoneal space leiomyosarcoma
+∞
24.4
23
*
A03FA01
ATC
metoclopramide; systemic, rectal
4.8
23.5
101
333
A04AA01
ATC
ondansetron; systemic, rectal
7.9
22.2
54
87
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
14.1
22.1
38
32
B01AB10
ATC
tinzaparin; parenteral
8.2
22.0
52
80
N02AA05
ATC
oxycodone; systemic
5.1
22.0
82
230
TPX10
NOMESCO Finland
Implantation of vascular injection port
17.3
21.5
34
23
L01XE11
ATC
[U] pazopanib; oral
+∞
21.2
20
*
Z51.5
ICD-10 Finland
Palliative care
8.5
20.6
47
68
KKB10
NOMESCO Finland
Excision of retroperitoneal tumour
219.1
19.9
20
*
LCD00
NOMESCO Finland
Hysterectomy
10.5
19.1
38
43
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
9.0
18.4
40
53
C49.43
ICD-10 Finland
Malignant tumor of connective tissue and soft tissue of the abdomen leiomyosarcoma
+∞
16.9
16
*
8890/3-C49.1
ICD-O-3
Leiomyosarcoma, NOS, of connective, Subcutaneous and other soft tissues of upper limb and shoulder
+∞
16.9
16
*
R19.0
ICD-10 Finland
Intra-abdominal and pelvic swelling, mass and lump
16.0
16.8
27
19
B01AB05
ATC
enoxaparin; parenteral
3.5
16.7
110
490
JN4AD
NOMESCO Finland
Body CT examination
5.7
16.3
50
108
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
7.6
16.2
39
61
L03AA02
ATC
filgrastim; parenteral
11.4
16.0
30
30
C78.0
ICD-10 Finland
Secondary malignant neoplasm of lung
16.4
15.8
25
17
C49.20
ICD-10 Finland
Malignant tumor of connective tissue and soft tissue of the lower extremity including the hip without histology
86.0
14.8
16
*
C49.13
ICD-10 Finland
Malignant tumor of connective tissue and soft tissue of upper extremity including shoulder leiomyosarcoma
+∞
14.7
14
*
D25.9
ICD-10 Finland
Leiomyoma of uterus, unspecified
5.8
14.2
42
86
D39.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Uterus
57.2
14.0
16
*
WX302
NOMESCO Finland
Thoracal epidural anesthesy
6.1
13.9
39
75
LAF10
NOMESCO Finland
Bilateral salpingo-oophorectomy
8.5
13.7
30
40
TPH90
NOMESCO Finland
Removal of fixed intravenous catheter
36.7
13.7
17
5
L03AA14
ATC
lipegfilgrastim; parenteral
14.2
13.2
22
17
NE1CG
NOMESCO Finland
Pelvic, hip and femur extensive MRI examination with high intensity magnet
14.2
13.2
22
17
WF049
NOMESCO Finland
Radiotherapy of metastasis
8.4
13.2
29
39
XX3DW
NOMESCO Finland
Time consuming IT work
4.3
13.1
52
147
D70.82
ICD-10 Finland
Drug-induced neutropenia
15.3
13.1
21
15
WX602
NOMESCO Finland
Repeated or continuing anesthesia shots throug a catheter
5.5
13.0
40
86
KBV02
NOMESCO Finland
Cystoscopic insertion of stent into ureter
18.8
12.8
19
11
WZC00
NOMESCO Finland
Planning of intervention or health care consultation
3.0
12.7
101
489
8890/3-C48.0
ICD-O-3
Leiomyosarcoma, NOS, of retroperitoneum
+∞
12.6
12
*
NFR30
NOMESCO Finland
Extended excision of soft tissue tumour of hip or thigh
+∞
12.6
12
*
8890/3-C49.4
ICD-O-3
Leiomyosarcoma, NOS, of connective, Subcutaneous and other soft tissues of abdomen
+∞
12.6
12
*
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
7.4
12.6
30
46
Z51.1
ICD-10 Finland
Chemotherapy session for neoplasm
14.5
12.2
20
15
D48.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Connective and other soft tissue
13.6
11.9
20
16
A04AD12
ATC
aprepitant; systemic
10.4
11.0
21
22
WF003
NOMESCO Finland
Adjuvant radiotherapy
7.7
10.9
25
36
C49.29
ICD-10 Finland
Malignant tumor of connective tissue and soft tissue of lower extremity including hip other or unspecified tumor
63.2
10.7
12
*
A04AA02
ATC
granisetron; systemic, transdermal
5.3
10.7
33
71
C54.12
ICD-10 Finland
Adenosquamous carcinoma of the endometrium
+∞
10.5
10
*
C49.53
ICD-10 Finland
Malignant tumor of connective tissue and soft tissue of the pelvis leiomyosarcoma
+∞
10.5
10
*
JN4CD
NOMESCO Finland
Very extensive body CT
7.6
10.4
24
35
NG1CG
NOMESCO Finland
Knee and lower leg extensive MRI examination with high intensity magnet
12.1
10.3
18
16
LX1XE
NOMESCO Finland
Other gynecological ultrasound examination
7.4
10.2
24
36
KBV12
NOMESCO Finland
Transluminal endoscopic removal of stent from ureter
42.1
10.1
12
*
WF001
NOMESCO Finland
Preoperative radiotherapy
42.1
10.1
12
*
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
5.0
10.0
32
72
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.5
9.9
120
709
WB113
NOMESCO Finland
Multiple adjuvant cytostatic therapy
6.1
9.7
26
47
166
Kela drug reimbursment
Dalteparin and tinzaparin (treatment for more than 6 months)
31.6
9.5
12
*
C49.2
ICD-10 Finland
Malignant neoplasm: Connective and soft tissue of lower limb, including hip
104.4
9.5
10
*
WX408
NOMESCO Finland
General anesthesy, balanced
2.7
9.5
81
393
8890/3-C55.9
ICD-O-3
Leiomyosarcoma, NOS, of uterus, NOS
+∞
9.4
9
*
343
Kela drug reimbursment
Pazopanib
+∞
9.4
9
*
WW500
NOMESCO Finland
Blood transfusion
6.8
9.4
23
37
WZC30
NOMESCO Finland
Teaching
3.2
8.8
50
187
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
9.1
8.5
17
20
C49.03
ICD-10 Finland
Malignant tumor of connective tissue and soft tissue of the head, face and neck Leiomyosarcoma
+∞
8.4
8
*
NBR30
NOMESCO Finland
Extensive or radical excision of soft tissue tumour of shoulder or upper arm
+∞
8.4
8
*
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
4.8
8.3
27
62
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
3.1
8.2
49
189
N13.3
ICD-10 Finland
Other and unspecified hydronephrosis
11.4
7.9
14
13
YN1BD
NOMESCO Finland
Extensive CT examination of extremities for dose design of radiotherapy
46.7
7.8
9
*
NGR30
NOMESCO Finland
Extensive or radikal excision of tumor of knee or lower leg
82.8
7.5
8
*
B02AA02
ATC
tranexamic acid; systemic
3.1
7.4
43
162
1820C
ICD-9 Finland
Malignant neoplasm of body of uterus, Corpus uteri, except isthmus[SARCOMA MYOMETRI]
+∞
7.3
7
*
C49.83
ICD-10 Finland
Overall malignant tumor of connective tissue and other soft tissue leiomyosarcoma
+∞
7.3
7
*
X77
ICPC
Malignant neopl genital female other
+∞
7.3
7
*
QBE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin of trunk
4.3
7.3
26
66
JJ2AT
NOMESCO Finland
Biopsy of liver with ultrasound guidance
8.4
7.2
15
19
ZZR00
NOMESCO Finland
Flap of skin
7.1
7.0
16
24
JN2CG
NOMESCO Finland
Extensive MRI examination of lower part of abdoment with high intensity magnet
9.8
6.9
13
14
R50.9
ICD-10 Finland
Fever, unspecified
2.9
6.9
45
181
LX1AE
NOMESCO Finland
Gynecological ultrasound examination as part of clinical examination
3.5
6.9
32
103
A79
ICPC
Malignancy NOS
9.1
6.7
13
15
C54.29
ICD-10 Finland
Unspecified uterine sarcoma
71.9
6.5
7
*
JN3CG
NOMESCO Finland
Extensive MRI examination of abdomen with high intensity magnet
71.9
6.5
7
*
KAC10
NOMESCO Finland
Total nephrectomy with capsule
14.9
6.5
10
7
TPH07
NOMESCO Finland
Cathetrisation of artery
3.0
6.4
36
133
NK1AT
NOMESCO Finland
Muscle biopsy with ultrasound guidance
18.7
6.3
9
5
JN3CD
NOMESCO Finland
Abdominal CT examination both without and with contrast
5.7
6.3
17
32
8890/3-C64.9
ICD-O-3
Leiomyosarcoma, NOS, of kidney, NOS
+∞
6.3
6
*
C48.02
ICD-10 Finland
Malignant tumor of the retroperitoneal space liposarcoma
+∞
6.3
6
*
YN1AD
NOMESCO Finland
CT examination of extremities for dose design of radiotherapy
+∞
6.3
6
*
YJ1CD
NOMESCO Finland
Very extensive CT examination of abdomen for dose design of radiotherapy
+∞
6.3
6
*
8890/3-C49.6
ICD-O-3
Leiomyosarcoma, NOS, of connective, Subcutaneous and other soft tissues of trunk, NOS
+∞
6.3
6
*
C54.9
ICD-10 Finland
Malignant neoplasm: Corpus uteri, unspecified
27.5
6.3
8
*
JAH00
NOMESCO Finland
Laparotomy
5.9
6.1
16
29
C03CA01
ATC
furosemide; systemic
2.1
6.0
85
507
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
30
59
5.68
15.02
2.5
2.1
0.4
0.3
u/ml
0.21
16
31
171
1117
2.91
12.47
21.4
9.6
4.1
4.1
e9/l
0.08
157
989
150
917
2.73
12.46
6.0
4.3
—
—
—
0
0
143
892
2.52
10.80
8.1
4.4
34.0
35.1
g/l
1.27
136
833
153
1018
2.42
9.54
8.4
7.1
1.2
1.2
mmol/l
0.69
124
865
145
947
2.37
9.37
8.1
6.1
1.2
1.2
mmol/l
0.41
137
858
92
501
2.37
9.00
3.3
2.4
—
—
—
0
0
21
55
4.09
7.43
1.8
1.4
—
—
—
0
0
62
307
2.38
7.33
5.0
1.8
30.8
29.5
s
0.65
62
299
35
131
2.96
7.21
7.7
8.6
95.5
94.0
%
1.43
35
131
37
144
2.86
7.11
1.9
1.6
—
—
—
0
0
62
324
2.24
6.39
2.2
1.9
—
—
—
0
0
46
216
2.40
6.05
6.5
3.7
—
—
—
0
0
14
32
4.59
5.85
4.1
3.9
56.8
63.9
%
0.69
14
32
171
1321
2.06
5.80
6.1
4.7
196.0
573.8
e6/l
—
7
25
10
17
6.10
5.67
1.7
1.6
—
—
—
0
0
45
217
2.33
5.56
1.8
1.8
—
—
—
0
0
71
413
2.03
5.46
6.9
3.1
2.5
2.5
mmol/l
0.09
64
361
48
242
2.23
5.33
5.9
9.0
0.3
1.5
mmol/l
1.56
33
191
107
726
1.86
5.16
3.8
3.1
—
—
—
0
0
13
31
4.38
5.16
4.0
3.0
3.3
5.6
e9/l
1.56
13
31
44
222
2.21
4.86
1.9
1.8
—
—
—
0
0
46
239
2.15
4.72
2.3
4.8
2.6
25.2
ug/l
0.71
34
201
12
29
4.31
4.68
1.8
1.6
—
—
—
0
0
104
727
1.77
4.36
10.2
3.4
2.3
2.4
mmol/l
0.32
96
630
92
621
1.79
4.34
6.7
2.9
46.2
33.0
u/l
0.86
86
597
12
31
4.02
4.31
1.4
1.6
—
—
—
0
0
12
31
4.02
4.31
1.4
1.6
—
—
—
0
0
11
27
4.22
4.21
1.5
1.6
—
—
—
0
0
10
23
4.50
4.13
1.7
1.6
—
—
—
0
0
185
1545
1.90
4.06
19.6
7.6
94.2
79.2
u/l
3.73
179
1444
84
566
1.75
3.92
3.6
3.0
0.6
0.6
e6/l
0.04
70
419
38
198
2.09
3.86
6.9
9.9
116.5
119.9
g/l
0.60
38
193
56
335
1.88
3.85
3.2
2.6
1.1
1.2
e6/l
0.05
37
181
12
35
3.56
3.67
1.4
1.6
—
—
—
0
0
8
13
6.33
3.53
1.5
1.5
—
—
—
0
0
13
42
3.22
3.42
1.6
1.7
—
—
—
0
0
52
315
1.83
3.42
3.6
2.9
4.7
2.6
e6/l
0.70
32
164
8
15
5.48
3.22
2.0
4.2
—
—
—
0
0
32
168
2.05
3.19
1.9
3.4
158.7
170.9
ng/l
0.08
25
151
25
120
2.21
3.12
1.4
1.4
—
—
—
0
0
7
12
5.97
3.04
1.6
1.3
—
—
—
0
0
14
52
2.80
2.94
1.6
1.7
—
—
—
0
0
88
641
1.59
2.90
2.9
3.2
2749.0
1409.2
ng/l
1.35
78
553
7
13
5.51
2.89
1.6
1.3
—
—
—
0
0
6
9
6.80
2.88
2.8
1.2
—
—
—
0
0
14
55
2.64
2.67
1.6
1.7
—
—
—
0
0
33
187
1.89
2.66
3.7
3.5
1.7
2.4
mmol/l
0.44
26
151
16
327
0.45
2.51
1.4
1.3
26.1
13.1
u/ml
0.25
11
121
34
539
0.57
2.42
1.6
1.6
1.3
1.3
mmol/l
0.23
25
456
7
17
4.21
2.38
2.9
1.5
26.0
17.2
ug/l
—
7
17
12
47
2.64
2.31
1.5
1.4
—
—
—
0
0
9
30
3.08
2.17
1.3
8.7
—
150.5
—
0
6
6
14
4.37
2.16
1.3
1.0
—
3.5
—
0
6
70
523
1.48
1.95
4.7
4.3
0.0
0.0
estimate
0.00
25
176
42
280
1.61
1.95
3.0
2.2
21.0
21.8
%
0.16
37
245
114
940
1.41
1.85
4.2
3.9
0.0
0.0
estimate
0.00
28
180
21
117
1.87
1.81
2.5
1.7
—
—
—
0
0
6
18
3.39
1.76
3.2
1.5
—
—
—
0
0
6
18
3.39
1.76
1.3
1.4
—
—
—
0
0
115
956
1.39
1.75
4.3
3.9
0.0
0.0
estimate
0.00
26
175
114
947
1.39
1.74
5.4
5.3
0.0
0.0
estimate
0.00
27
175
5
13
3.90
1.72
1.2
1.9
—
—
—
0
0
5
13
3.90
1.72
1.2
1.9
—
—
—
0
0
63
476
1.44
1.64
2.0
2.2
3.1
3.2
mg/l
0.13
54
418
5
14
3.62
1.62
2.2
2.2
—
—
—
0
0
6
20
3.05
1.59
1.2
1.2
—
—
—
0
0
21
338
0.58
1.56
1.3
1.3
15.9
34.9
iu/ml
—
7
112
0
42
0.00
1.54
0.0
1.3
—
56.2
—
0
5
14
72
2.00
1.52
5.2
2.1
504.0
886.7
ug/l
0.26
14
66
206
1920
1.56
1.50
32.3
15.3
31.3
22.8
mg/l
2.72
193
1526
5
16
3.17
1.44
1.4
1.2
65.0
48.8
u/l
—
5
8
13
68
1.96
1.36
2.1
2.6
—
—
—
0
0
6
24
2.54
1.31
1.2
1.1
—
—
—
0
0
51
389
1.40
1.25
4.0
4.0
26.2
311.3
ng/l
2.08
44
322
6
25
2.44
1.25
1.0
1.4
—
—
—
0
0
15
87
1.77
1.18
2.9
2.2
—
—
—
0
0
18
278
0.62
1.15
1.4
1.4
—
—
—
0
0
11
58
1.94
1.14
1.2
1.8
—
—
—
0
0
193
1803
1.38
1.12
33.8
14.5
76.4
76.5
ml/min/173m2
0.03
181
1497
7
31
2.30
1.11
1.1
1.6
—
—
—
0
0
7
32
2.22
1.09
1.3
1.6
—
—
—
0
0
7
32
2.22
1.09
1.3
1.6
—
—
—
0
0
7
32
2.22
1.09
1.3
1.6
—
—
—
0
0
10
52
1.96
1.08
1.1
1.3
—
—
—
0
0
7
33
2.15
1.06
1.3
1.6
—
—
—
0
0
7
33
2.15
1.06
1.3
1.6
—
—
—
0
0
27
190
1.48
1.02
1.6
2.5
13.7
7.0
ug/l
0.28
21
167
23
157
1.51
1.00
5.3
2.9
56.9
59.3
ml/min/173m2
0.12
12
63
183
1937
0.76
0.97
4.4
5.3
2.6
2.7
mmol/l
0.94
163
1775
6
27
2.25
0.94
1.3
1.0
—
—
—
0
0
11
63
1.78
0.91
1.1
1.2
—
—
—
0
0
134
1210
1.25
0.91
4.5
3.1
74.5
47.5
u/l
2.03
128
1119
6
29
2.10
0.90
1.5
1.3
—
—
—
0
0
85
731
1.25
0.89
5.0
4.2
—
—
—
0
0
11
64
1.75
0.87
1.1
1.2
—
—
—
0
0
94
821
1.24
0.85
4.3
4.0
30.6
39.9
ng/l
0.48
80
595
8
45
1.80
0.85
1.5
1.8
—
—
—
0
0
8
46
1.76
0.83
1.4
1.4
—
—
—
0
0
8
46
1.76
0.83
1.4
1.4
—
—
—
0
0
160
1482
1.25
0.83
4.7
4.1
14.9
14.9
pmol/l
0.06
150
1319
33
253
1.35
0.81
6.5
6.8
—
—
—
0
0
0
28
0.00
0.76
0.0
1.7
—
—
—
0
0
8
134
0.58
0.76
2.4
1.7
—
—
—
0
0
9
54
1.69
0.75
1.2
1.4
—
—
—
0
0
5
24
2.11
0.75
1.0
1.1
422.8
264.1
pmol/l
—
5
19
179
1883
0.80
0.74
4.0
4.6
1.5
1.5
mmol/l
0.42
159
1729
5
25
2.02
0.73
1.4
1.3
—
—
—
0
0
9
58
1.57
0.70
1.1
1.4
—
—
—
0
0
181
1896
0.81
0.67
3.9
4.7
4.5
4.7
mmol/l
1.08
163
1748
10
62
1.64
0.66
1.3
1.3
—
—
—
0
0
71
809
0.83
0.66
2.4
2.2
75.5
78.8
nmol/l
0.52
63
719
15
104
1.47
0.64
3.3
2.4
1.2
1.2
%
0.10
15
104
173
1814
0.83
0.60
6.2
6.1
43.4
40.6
mmol/mol
1.98
152
1683
51
433
1.23
0.59
1.9
1.7
2.0
1.2
mg/l
0.87
39
355
0
22
0.00
0.59
0.0
1.2
—
—
—
0
0
0
22
0.00
0.59
0.0
1.2
—
—
—
0
0
0
22
0.00
0.59
0.0
1.2
—
—
—
0
0
0
22
0.00
0.59
0.0
1.2
—
—
—
0
0
0
22
0.00
0.59
0.0
1.2
—
—
—
0
0
5
90
0.55
0.57
4.0
1.6
—
—
—
0
0
12
82
1.49
0.55
2.9
1.9
—
—
—
0
0
7
108
0.64
0.50
1.3
1.5
—
—
—
0
0
8
117
0.67
0.47
1.5
1.6
—
—
—
0
0
7
51
1.38
0.44
1.6
1.2
—
—
—
0
0
48
420
1.18
0.42
1.6
1.8
515.6
473.7
pmol/l
0.19
34
347
36
418
0.84
0.41
2.0
1.7
1425.3
1206.7
nmol/l
0.62
23
318
0
17
0.00
0.41
0.0
1.0
—
448.1
—
0
10
0
17
0.00
0.41
0.0
1.2
—
—
—
0
0
0
17
0.00
0.41
0.0
1.2
—
7.1
—
0
12
0
17
0.00
0.41
0.0
1.1
—
40.6
—
0
9
5
37
1.36
0.37
1.6
1.7
—
—
—
0
0
12
90
1.35
0.36
1.1
1.3
—
—
—
0
0
6
41
1.48
0.36
1.0
1.2
4.4
3.9
mmol/l
—
6
36
175
1809
0.88
0.36
3.8
4.2
1.3
1.3
mmol/l
0.65
154
1651
7
57
1.23
0.29
2.6
2.0
25.4
25.1
mmol/l
—
7
45
23
266
0.85
0.26
3.7
4.7
33.2
31.5
%
0.31
17
176
98
1028
0.92
0.23
2.6
2.6
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.4
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.4
—
—
—
0
0
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
55
511
1.10
0.21
2.6
2.7
342.7
7983.2
umol/l
2.65
47
435
0
12
0.00
0.21
0.0
1.5
—
—
—
0
0
0
12
0.00
0.21
0.0
2.2
—
13.6
—
0
12
0
12
0.00
0.21
0.0
1.5
—
—
—
0
0
5
43
1.17
0.21
1.0
1.3
60.4
29.3
iu/l
—
5
36
7
62
1.13
0.17
1.9
1.6
—
—
—
0
0
185
1882
0.92
0.16
4.4
4.9
6.2
6.0
mmol/l
0.75
165
1722
53
500
1.08
0.15
1.5
1.5
22.3
21.1
nmol/l
0.27
46
418
11
95
1.17
0.12
1.0
1.0
—
—
—
0
0
27
291
0.92
0.11
3.4
3.2
0.7
0.8
ug/l
0.31
22
200
165
1671
0.96
0.08
31.7
16.3
37.4
39.3
%
2.16
108
1161
40
386
1.04
0.05
6.0
4.7
19.2
21.4
%
0.59
25
205
28
269
1.05
0.04
1.3
1.3
—
—
—
0
0
80
789
1.02
0.03
2.9
2.7
179.3
118.5
ug/l
1.57
75
723
147
1479
0.98
0.02
3.7
4.1
17.7
13.3
mm/h
1.44
126
1351
82
828
0.99
0.01
1.9
2.0
91.6
95.4
pmol/l
0.28
46
406
11
104
1.06
0.01
3.3
3.5
4.3
4.5
pmol/l
0.40
11
90
180
1794
1.01
0.00
5.3
4.9
2.1
2.6
mu/l
0.34
165
1618
41
405
1.01
0.00
1.2
1.2
1.0
1.6
u/ml
0.61
14
119
0
9
0.00
0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
0.00
0.0
2.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.6
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
15.4
—
0
5
0
8
0.00
0.00
0.0
2.0
—
70.4
—
0
8
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
6
64
0.94
0.00
7.0
4.2
—
3.2
—
0
8
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: C3_LEIOMYOSARCOMA – Leiomyosarcoma
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).